Merrimack Pharmaceuticals Inc (NASDAQ:MACK) reported that the U.S. Food and Drug Administration has granted orphan drug designation to its MM-141 for the treatment of pancreatic cancer. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is trading in the 52-week range between $2.05 and $9.59. The orphan status is given to drugs for disorders that affect fewer than 200,000 people in the United States. The company said the designation will potentially provide it with seven-year marketing exclusivity for MM-141 and other benefits, if the drug is approved by the FDA. A Phase 2 study testing MM-141 in combination with nab-paclitaxel and gemcitabine in front line pancreatic cancer is expected to start in 2015.Nu Skin Enterprises, Inc. (NYSE:NUS), a personal care product direct seller, announced Q3 results that beat the Street view on EPS and total revenues but issued Q4 guidance below analyst expectations. The company reported Q3 adjusted EPS of $1.12, down from $1.80 a year ago but beating analyst estimates of $0.93. Total revenues of $638.80 million were down from $908.29 million in Q3 2013 but topped analyst projections of $630.07 million for the quarter. Nu Skin Enterprises, Inc. (NYSE:NUS) expects Q4 revenue of $590 million to $610 million, with earnings per share of $0.72 to $0.77. Analysts had expected revenues of $659 million and EPS of $1.01."The strength of the U.S. dollar will reduce our fourth-quarter results," said Ritch Wood, chief financial officer. "We anticipate the impact from currency on fourth-quarter revenue will be about $50 million when compared to currency rates in the prior-year period and about $30 million sequentially. Additionally, while we anticipate core business trend improvement, we estimate $20 million of LTO sales in the fourth quarter versus $350 million of LTO sales in the fourth quarter of 2013, and $80 million of LTO sales in the third quarter of 2014." The company declared a quarterly dividend of $0.34 per share, consistent with the previous quarter's payout, which will be paid on December 3 to stockholders of record on November 21.Criteo SA (ADR) (NASDAQ:CRTO) reported better-than-expected Q3 earnings and revenue, and guiding Q4 above the consensus estimate. The company, which develops performance marketing technology, reported net Q3 net income of EUR 11.4 million, or EUR 0.18 per share. Adjusted earnings were EUR 0.25, beating the consensus estimate from Capital IQ of EUR 0.07 per share. For the same quarter last year, Criteo SA (ADR) (NASDAQ:CRTO) reported net income of EUR 2.8 million, or EUR 0.05 per share. Revenue (ex-Traffic Acquisition Costs) of EUR 77.6 million beat analyst estimates of EUR 72.66 million versus EUR 46.8 million for Q3 2013. For Q4 2014, Criteo expects ex-TAC revenue of EUR 89 million to EUR 91 million, well above estimates of EUR 81 million. Adjusted EBITDA is expected to rise to EUR 27 million-EUR 29 million from Q3's EUR 19.8 million. Shares of CRTO last traded at $35.20 with a 52-week range of $25.16 to $60.95.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
